Tempus AI, Inc. announced that it had entered into a series of agreements with Bristol-Myers Squibb Company and Pathos AI, Inc. to expand the use of Tempus’s…
Tempus AI, Inc. (TEM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 23, 2026, Tempus AI, Inc. (“Tempus”) announced that it had entered into a series of agreements with Bristol-Myers Squibb Company (“BMS”) and Pathos AI, Inc. (“Pathos”) to expand the use of Tempus’s de-identified multimodal real-world data, data
How this was made
The 30-second read
Why it matters
The disclosed cash payments represent a material revenue boost for Tempus and expand BMS’s data assets, while the partnership’s success hinges on data delivery and integration.
Market read
First‑report of a $192.5 M multi‑year data‑license deal, likely to move Tempus shares and inform pharma sector sentiment.
What to watch
Execution risk on delivering the promised data volume and quality could affect the realized value of the agreements.
Background
Tempus AI filed an 8‑K announcing multi‑year licensing agreements with Bristol‑Myers Squibb and Pathos AI, detailing payment terms and data scope.
Ticker impact
Tempus AI disclosed $192.5 million in aggregate cash payments from new data‑license agreements with Bristol‑Myers Squibb and Pathos AI.
likely upward pressure as the market prices in the new revenue stream
First‑report 8‑K with concrete payment amounts; cash component is sizable for a micro‑cap.
Bristol‑Myers Squibb entered a $137.5 million oncology data license and a $55 million neurology data deal with Tempus AI.
minimal immediate move; long‑term upside if data improves R&D efficiency
Deal is a partnership, not a direct earnings driver; impact depends on future research outcomes.
Market effects
Strengthens the biotech data‑analytics niche and may spur similar licensing deals across pharma.
U.S. biotech and pharma sectors see modest positive sentiment.
Highlights growing importance of real‑world evidence in drug development worldwide.
Counterpoint
The cash outlay for BMS could be seen as a cost without guaranteed ROI, potentially weighing on its margin outlook.
Key entities
- companyTempus AI, Inc.
Provider of de‑identified multimodal real‑world data and analytics platforms.
- companyBristol‑Myers Squibb
Large pharmaceutical company gaining data access for oncology and neurology programs.
- companyPathos AI, Inc.
AI firm collaborating with BMS on drug development using licensed data.
